EP
NVCR icon

Essential Partners’s NovoCure NVCR Stock Holding History

Essential Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Sell
951
-307
-24% -$4.64K 0.01% 1038
2026
Q1 		$13.7K Buy
1,258
+716
+132% +$8.94K ﹤0.01% 1091
2025
Q4 		$7.01K Buy
542
+130
+32% +$1.67K ﹤0.01% 1296
2025
Q3 		$5.32K Buy
412
+394
+2,189% +$5.26K ﹤0.01% 1402
2025
Q2 		$320 Buy
+18
New +$314 ﹤0.01% 1824

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Essential Partners's NVCR Position: Q2 2026 in Review

Essential Partners reduced its NovoCure (NVCR) stake by 24% in Q2 2026, selling an estimated $4.64K and leaving 951 shares worth $14.4K. The position accounts for 0.01% of the portfolio, ranked #1038.

Essential Partners first reported a position in NVCR in Q2 2025 and has held it in 5 quarters since. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Essential Partners held 951 shares of NovoCure worth $14.4K as of Q2 2026.
  • Essential Partners sold 307 NovoCure shares in Q2 2026, an estimated $4.64K.
  • NovoCure made up 0.01% of Essential Partners's portfolio in Q2 2026, its #1038 holding.
  • Essential Partners first reported a position in NovoCure in Q2 2025 and has held it in 5 quarters since.
  • 216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.